P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2027

P=N/A, N=30, Completed, University Health Network, Toronto | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025

P=N/A, N=18, Completed, University of Leicester | Recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2025 --> Aug 2025

Early clinical data show encouraging antitumor response of CJRB-101 plus pembrolizumab in ICI-naïve metastatic NSCLC with PD-L1 >50%.

P2, N=34, Not yet recruiting, City of Hope Medical Center

P1/2, N=80, Recruiting, Massachusetts General Hospital | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Dec 2026 --> Mar 2028

P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2028 | Trial primary completion date: May 2027 --> Oct 2028

Using a novel phospho-specific monoclonal antibody, we show that TPR is phosphorylated at Ser2155 following EGFR activation via the canonical RAS-RAF-MEK-ERK MAPK cascade, placing TPR downstream of MAPK pathway activation...Finally, immunohistochemical analysis reveals elevated TPR phosphorylation in serous ovarian carcinoma and heterogeneous phosphorylation patterns in triple-negative breast cancer, two tumor types frequently characterized by MAPK pathway hyperactivation. Together, these findings uncover a previously unappreciated role for TPR as a MAPK-responsive nuclear factor and support a model in which NPC-associated components fine-tune mitogen-induced transcriptional responses.

P2, N=204, Recruiting, MRM Health NV | Not yet recruiting --> Recruiting

P1/2, N=6, Not yet recruiting, MaaT PHARMA

The probiotic Clostridium butyricum strain MIYAIRI 588 (CBM588) improves response rates and overall survival in patients receiving immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer and metastatic renal cell carcinoma but the mechanism underlying this benefit remains unclear...Across the patient cohort, higher post-treatment frequencies of CD69+ Vδ2 T-cells were associated with improved survival and more favourable clinical outcomes. These findings provide a potential mechanism by which manipulation of the intestinal microflora might contribute to cancer prognosis through effects on immune effector cells with intrinsic anticancer properties.

P1, N=48, Active, not recruiting, Bloom Science Australia Pty Ltd | Not yet recruiting --> Active, not recruiting